Dr Kerwin Low is Vice-President, Regulatory Affairs, Emerging Markets, at Moderna Therapeutics.

Prior to joining Moderna, he served as the Regulatory Affairs Lead in APAC at the Coalition for Epidemic Preparedness Innovations (CEPI). He has more than 16 years of experience in International Regulatory Affairs, having held roles in Takeda as Vice President Regulatory Affairs for the Emerging Markets Region, in GlaxoSmithKline leading Asia Regulatory Affairs for Pharmaceuticals and Vaccines, in Novartis where he headed Regulatory Affairs for the International and Latin American regions in their Vaccines Division, and in Johnson & Johnson where he was Asia Pacific Regulatory Affairs Director for their Medical Devices division. 

Dr Kerwin also has experience as a regulator, having worked for 5 years with the Singapore Health Sciences Authority during which he took on roles of increasing responsibility, including leading the Drug Registration and Clinical Trials branches of the agency. 

Prior to embarking on a career in Regulatory Affairs, Dr Kerwin was an Academic Staff member in the Department of Pharmacology in the National University of Singapore’s Medical Faculty. During this period, he held concurrent appointments as Research Scientist in the Defense Medical Research Institute (DMRI), in Singapore’s Ministry of Defence and as a Principal Investigator in the national Newater study team in collaboration with Singapore’s Public Utilities Board (PUB). He continues to serve alongside a team of international experts in the PUB’s External Audit Panel.

Dr Kerwin holds a PhD degree in Pharmacology and an Honors degree in Pharmacy from the National University of Singapore.